

UC Davis

UC Davis Previously Published Works

Title

A Bifunctional Anti-Amyloid Blocks Oxidative Stress and the Accumulation of Intraneuronal Amyloid-Beta

Permalink

<https://escholarship.org/uc/item/4gq5n2bw>

Journal

Molecules, 23(8)

ISSN

1431-5157

Authors

Hilt, Silvia

Altman, Robin

Kálai, Tamás

et al.

Publication Date

2018

DOI

10.3390/molecules23082010

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Article

A Bifunctional Anti-Amyloid Blocks Oxidative Stress and the Accumulation of Intraneuronal Amyloid-Beta

Silvia Hilt¹, Robin Altman², Tamás Kálai³, Izumi Maezawa⁴, Qizhi Gong⁵, Sebastian Wachsmann-Hogiu^{6,7}, Lee-Way Jin⁴ and John C. Voss^{1,*} 

¹ Department of Biochemistry & Molecular Medicine, University of California, Davis, CA 95616, USA; slhilt@ucdavis.edu

² Department of Biological Sciences, California State University Sacramento, Sacramento, CA 95819, USA; altman@csus.edu

³ Institute of Organic and Medicinal Chemistry, University of Pécs, H-7624 Pécs, Szigeti st. 12., H-7624 Pécs, Hungary; tamas.kalai@aok.pte.hu

⁴ Medical Investigation of Neurodevelopmental Disorders (M.I.N.D.) Institute and Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA 95817, USA; imaezawa@ucdavis.edu (I.M.); lwjin@ucdavis.edu (L.-W.J.)

⁵ Department of Cell Biology and Human Anatomy, School of Medicine, University of California, Davis, Davis, CA 95616, USA; qzgong@ucdavis.edu

⁶ Department of Pathology and Laboratory Medicine, and Center for Biophotonics, University of California Davis, Sacramento, CA 95817, USA; sebastian.wachsmannhogiu@mcgill.ca

⁷ Department of Bioengineering, McGill University, Montreal, QC H3A OE9, Canada

* Correspondence: jcvoss@ucdavis.edu; Tel.: (530) 754-7583

Academic Editors: Birgit Hutter-Paier and Stephan Schilling

Received: 1 July 2018; Accepted: 8 August 2018; Published: 12 August 2018



Abstract: There is growing recognition regarding the role of intracellular amyloid beta ($A\beta$) in the Alzheimer's disease process, which has been linked with aberrant signaling and the disruption of protein degradation mechanisms. Most notably, intraneuronal $A\beta$ likely underlies the oxidative stress and mitochondrial dysfunction that have been identified as key elements of disease progression. In this study, we employed fluorescence imaging to explore the ability of a bifunctional small molecule to reduce aggregates of intracellular $A\beta$ and attenuate oxidative stress. Structurally, this small molecule is comprised of a nitroxide spin label linked to an amyloidophilic fluorene and is known as spin-labeled fluorene (SLF). The effect of the SLF on intracellular $A\beta$ accumulation and oxidative stress was measured in MC65 cells, a human neuronal cell line with inducible expression of the amyloid precursor protein and in the N2a neuronal cell line treated with exogenous $A\beta$. Super-resolution microscopy imaging showed SLF decreases the accumulation of intracellular $A\beta$. Confocal microscopy imaging of MC65 cells treated with a reactive oxygen species (ROS)-sensitive dye demonstrated SLF significantly reduces the intracellular $A\beta$ -induced ROS signal. In order to determine the contributions of the separate SLF moieties to these protective activities, experiments were also carried out on cells with nitroxides lacking the $A\beta$ targeting domain or fluorene derivatives lacking the nitroxide functionality. The findings support a synergistic effect of SLF in counteracting both the conformational toxicity of both endogenous and exogenous $A\beta$, its promotion of ROS, and $A\beta$ metabolism. Furthermore, these studies demonstrate an intimate link between ROS production and $A\beta$ oligomer formation.

Keywords: amyloid beta; Alzheimer's disease; bifunctional drug; $A\beta$ oligomer; oxidative stress; intraneuronal $A\beta$; intracellular $A\beta$; nitroxide antioxidant; spin label

1. Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive and irreversible cognitive decline. Hallmarks of AD pathology include the deposition of extracellular insoluble amyloid beta ($A\beta$) plaques and hyper-phosphorylation of tau protein, which lead to intracellular accumulation of neurofibrillary tangles (NFT). More recently, however, stronger emphasis has been placed on two interdependent initiators of the neurodegenerative cascade in AD: accumulation of small, soluble, intracellular $A\beta$ oligomers ($A\beta O$) and the subsequent $A\beta O$ -induced neuro-inflammation that leads to the formation of reactive oxygen species (ROS) and cellular damage [1–3].

Numerous mechanisms have been proposed to account for $A\beta$ toxicity since the peptide has been found to interact with and/or dysregulate a plethora of cellular systems. While most experimental and clinical efforts have focused on extracellular $A\beta$, there is growing evidence supporting a significant role for intracellular oligomeric $A\beta O$ in the etiology of AD [4,5]. Intra-neuronal $A\beta$ precedes both intracellular NFTs and extracellular amyloid deposits [6] and has profound effects on neuronal health [7]. For example, intracellular $A\beta$ was found to be considerably more toxic than extracellular $A\beta$ [5,8]. The two pools of $A\beta$ seem to exist in a dynamic equilibrium [9], which means targeting intracellular $A\beta$ may also influence the levels of extracellular $A\beta O$.

Many studies report oxidative stress plays a major role in AD progression. Oxidative stress occurs when there is a physiological imbalance between a high level of ROS and the body's ability to produce enough ROS scavengers to counteract the ROS [10–12]. While oxidative stress is a major indicator of aging, increased levels of oxidative stress markers are present in the brains of patients in different stages of AD. For example, lipid peroxidation marker levels are consistently elevated during the early stages of AD when compared to patients with mild cognitive impairment (MCI), late stage AD, or those with Parkinson's disease [13]. In addition to the modification of lipids, proteins, and DNA, lipid peroxidation byproducts produced during oxidative stress damage mitochondria and up-regulate tau phosphorylation [14,15]. Although the mechanism of the ROS cascade in AD is unclear, $A\beta$ is an efficient generator of hydrogen peroxide [16], which can lead to mitochondrial impairment and further generation of ROS [17]. $A\beta$ may also interact directly with the respiration chain of mitochondria, resulting in dysfunction and elevated ROS production [18]. This is consistent with clinical observations correlating mitochondrial oxidative damage with disease progression in AD patients [12,19].

We have, therefore, focused our efforts on designing targeted bifunctional compounds that convert $A\beta O$ into a nontoxic state and also block $A\beta O$ -induced cellular oxidative damage. We have previously described one such compound known as the spin-labeled fluorene (SLF, Figure 1) [20–22]. SLF is comprised of a fluorene core that binds to $A\beta$ with high affinity [22] and stabilizes $A\beta O$ into small nontoxic oligomers [20,23]. The bifunctionality of SLF arises from its nitroxide spin label moiety, which provides catalytic antioxidant activity [24,25]. The ability of sterically hindered cyclic nitroxides to serve as mimics of superoxide dismutase within cells has led to their consideration as anti-cancer [26], radioprotective [27], and anti-aging [28] agents. In this study, we use confocal and super-resolution microscopy to demonstrate that SLF blocks $A\beta$ -induced ROS generation within cultured neurons, inhibits intra-neuronal oligomer formation, and facilitates clearance of intra-neuronal $A\beta$. Furthermore, by evaluating the functional components of SLF independently, we provide new insights on the interdependence of oxidative stress and $A\beta O$ toxicity.




Figure 1. (A) The chemical structure of the spin-labeled fluorene (SLF). The amyloid-targeting domain is shown in red and the nitroxide spin label moiety is shown in black. The diamagnetic form of SLF (SLF^{dm}) that lacks the nitroxyl antioxidant capacity is shown in (B). (C) The structure of the antioxidant MitoTEMPO.

2. Results

2.1. In Cultured Neurons, the Bifunctional Activity of SLF Offers Superior Protection against the Toxicity of both Exogenous A β and A β Peptide Generated Intracellularly

We have previously shown that SLF is a more potent protector against A β toxicity compared to the parent fluorene molecule lacking the nitroxide spin label moiety [21]. Both SLF and the parent fluorene bind A β O, reverse the peptide aggregation, and block A β toxicity [20–23]. In order to further evaluate the significance of the antioxidant functionality in SLF protection, we compared the ability of SLF, a diamagnetic version of SLF (SLF^{dm}), and MitoTEMPO, which is a potent mitochondrial-targeted nitroxide antioxidant, to counteract A β toxicity in cultured N2a neurons (Figure 2A). After reaching 80% confluence, the cultured cells were co-treated with A β and with either the vehicle (DMSO) or the aforementioned compounds to a final concentration of 1 μ M and 2 μ M, respectively. The cultured cells were incubated at 37 °C for 24 hours. The MTT assay was performed to measure cell survival and one-way ANOVA data on the percentage survival of cells show that when SLF is added to N2a cells treated with exogenous A β , there is about an eight-fold increase in cell survival (Figure 2A) compared to cells treated with exogenous A β alone (Figure 2A). Comparatively, the SLF^{dm} increases cell survival by only about three-fold, which highlights the significance of the nitroxyl moiety in ROS protection (Figure 2A). The MitoTEMPO compound that has an ROS scavenger moiety similar to SLF also increases cell viability by about seven-fold (Figure 2A). Similarly, we compared the protection of the SLF moieties in the human neuroblastoma MC65 cell line, which generates large amounts of intraneuronal A β by overexpressing the amyloid precursor protein (APP) through Tet-Off transcriptional regulation [29] (Figure 2B). Control cells were grown with tetracycline (+TC, Figure 2B) until the cells reached 80% confluence, at which point the A β challenge was initiated by removing tetracycline from the culture media. The compounds (SLF, SLF^{dm}, and MitoTEMPO) were added to a final concentration of 2 μ M. The cells were incubated at 37 °C for 72 hours, which was followed by MTT analysis of cell

survival. Statistical analysis shows SLF exerts maximum protection in cells overexpressing APP precursor protein and has about a 14-fold increase in cell survival (Figure 2B) over APP-induced cells (Figure 2B). SLF^{dm} increases cell survival by about five-fold (Figure 2B) while the MitoTEMPO compound increases cell survival by about 10-fold (Figure 2B). Overall, the cell survival assay showed a similar pattern for protection against both exogenous and endogenous A β with SLF inducing the most protection, followed by MitoTEMPO and SLF^{dm} (Figures 2A and 2B). The effect of APP induction and compound treatment on MC65 cell morphology is shown in Figure 2C. MC65 cells grown in the absence of APP induction (+TC) maintain cell morphology at three days while MC65 cells induced for APP expression (–TC) exhibit 100% alteration of cell morphology. APP-induced cells in the presence of 2 μ M SLF show unaltered cell morphology, which is indicative of SLF's ability to protect neurons from A β -induced cellular damage. In contrast, both SLF^{dm} and MitoTEMPO offer limited protection of neuronal morphology.




Figure 2. Protection against A β toxicity by SLF compared to agents bearing only an antioxidant or anti-amyloid activity. Neuronal viability by the MTT assay was determined for exogenous A β (N2a cells) and endogenous A β (MC65 cells) after 72 hours. (A) 1 μ M exogenous A β was added to cultured N2a neurons and cell viability was compared to the +A β group. The effect of 2 μ M SLF, SLF^{dm}, and MitoTEMPO co-addition on the survival of A β O-treated N2a cells is given by the green, orange, and blue bars, respectively. The ability of SLF and its independent functionalities to protect against A β toxicity in MC65 neurons containing Tet-Off inducible gene expression for the A β precursor (APP) is shown in (B). The viability of the non-induced (+TC) cells is given by the red bar. The effect of 2 μ M SLF, SLF^{dm} and MitoTEMPO addition to the APP-induced (–TC) cell survival is given by the green, orange, and blue bars, respectively, and is compared to the –TC group. For both (A) and (B), compounds were added upon APP induction and cell survival was measured 72 hours later. Statistical analyses of cell counts by one-way ANOVA gives * $p < 0.01$, ** $p < 0.001$, $n = 9$. Error bars represent the standard error as described in the Methods section. Panel (C) shows light microscopy images of MC65 cell cultures three days without APP induction (i), with APP induction (ii), with APP induction in the presence of 2 μ M SLF (iii), with APP induction in the presence of 2 μ M SLF^{dm} (iv), and with APP induction in the presence of 2 μ M MitoTEMPO (v).

2.2. SLF's Nitroxide Component Plays a Key Role in Decreasing A β -Induced Oxidative Stress in a Human Neuroblastoma Cell Line (MC65) Overexpressing the Amyloid Precursor Protein

The role of A β in increasing oxidative stress has been well-documented using various methods to detect reactive oxidative species [30–32]. To determine if treatment with SLF attenuates A β -induced ROS production, we cultured the MC65 neurons in the presence and absence of SLF upon induction of the A β precursor, APP. Intracellular A β is known to start accumulating as early as 4 hours after TC removal in the

MC65 cell line and most unprotected cells die after three days. In order to avoid the detection of oxidative changes due to cell death toxicity, we imaged cells stained with the ROS-sensitive dye CellROX at the 24-hour time period [33]. As shown in Figure 3B, expression-induced cells show a clear red CellROX signal, which indicates a high level of oxidative stress. When APP-expressing cells are treated with SLF, ROS levels are significantly lowered (Figure 3C). In order to confirm the role of the nitroxide spin label moiety in attenuating A β -induced oxidative stress, we also treated APP-expressing cells with the diamagnetic version of SLF (SLF^{dm}), which lacks the catalytic antioxidant functionality. As shown in Figure 3D, SLF^{dm} only partially lowers ROS levels relative to the vehicle control. The significance of the nitroxide moiety alone is confirmed by the ability of the nitroxide-based antioxidant MitoTEMPO to attenuate oxidative stress in A β -challenged neurons (Figure 3E). Quantification of CellROX intensities is given in Figure 4. The superior performance of SLF (Figure 4) in lowering oxidative stress suggests its ability to provide a targeted antioxidant activity that underlies its potency in protecting against A β toxicity.




Figure 3. The nitroxide moiety of SLF has extensive ROS scavenging properties in cultured neuronal cells induced to overexpress the amyloid precursor protein (APP). Confocal microscopy images show A β -induced ROS signal reported by the fluorogenic dye CellRox Deep Red (red punctae in image) in MC65 human neuroblastoma cells when APP expression is turned on (B) relative to the control (A). In cells that are overexpressing APP, SLF greatly attenuates the ROS signal (C). SLF lacking the nitroxyl moiety (D) and the MitoTEMPO antioxidant (E) provide lower ROS scavenging activity compared to SLF. In addition to the CellROX images (left column), the DAPI nuclear stain (middle column) and the merged DAPI-CellRox images (right column) are shown. Scale bar represents 20 μ m.




Figure 4. Quantification of mean fluorescence intensity signal of A β -induced ROS signal (see Figure 3) in human neuronal cells overexpressing the amyloid precursor protein (APP). The effect on A β -induced ROS signal of SLF, SLF^{dm}, and MitoTEMPO addition to the APP-induced cells (–TC) is given by the green, orange, and blue bars, respectively, and is compared to the –TC group. Statistical analyses of fluorescence intensity by one-way ANOVA gives * $p < 0.01$, ** $p < 0.001$ for $n = 3$. Error bars represent the standard error as described in the Methods section.

2.3. The Nitroxide Group of the SLF Compound Plays a Key Role in Decreasing Exogenous A β -Induced Oxidative Stress

To determine the ability of SLF to attenuate oxidative stress from exogenous A β , we first measured A β O-induced oxidative stress in N2a cultured neurons (Figure 5). We then evaluated the abilities of SLF, MitoTEMPO, and SLF^{dm} to attenuate the oxidative stress resulting from an exogenous A β O challenge. We co-treated N2a cells with the compounds (2 μ M final concentration) and exogenous A β (1 μ M final concentration), incubated the cultures for 24 hours at 37 °C, and then imaged the CellROX signal. Both SLF and MitoTEMPO strongly inhibit ROS generation in A β -challenged neurons (Figures 5C and 5E). SLF^{dm} offers partial protection against ROS generation, which suggests that conformational modulation of A β by the fluorene moiety can regulate the ability of A β to promote oxidative stress. A quantification of ROS signal in the N2a cells is given in Figure 6.

2.4. SLF Attenuates the Cytoplasmic Accumulation of Intracellular A β in a Human Neuroblastoma Cell Line Overexpressing the Amyloid Precursor Protein Shown by Super-Resolution Structured Illumination Imaging

To investigate the specific sub-cellular localization of A β deposition and SLF's role in modulating this process, we cultured MC65 neurons expressing the APP protein without TC for 24 hours in the presence of SLF or vehicle. We assessed A β deposits by super-resolution microscopy using the FSB stain, which is a known amyloid dye (Figure 7) [34,35]. Cells grown in the presence of TC served as controls (Figure 7A). In cells overexpressing the APP protein, there is significant FSB staining of accumulated intracellular A β (green staining, Figure 7B). The bulk of the deposits surround the nucleus and appear to distort and protrude into the nuclear membrane (Figure 7B). As shown in Figure 7C,

there is a greatly reduced FSB signal in cells treated with SLF, which indicates that SLF effectively blocks intracellular A β accumulation in cells overexpressing APP.




Figure 5. The nitroxide moiety of SLF has extensive ROS scavenging properties in N2a cells treated with 1 μ M exogenous A β . ROS levels were imaged by confocal microscopy for the fluorogenic dye CellRox Deep Red (red punctae in image). A slight generation of ROS is evident with the vehicle control (A). Addition of A β elicits a strong ROS response (B). Images show decreased levels of the A β -induced ROS signal in the presence of SLF (C) while moderately high levels of ROS are evident in cells treated with the SLF lacking the nitroxyl moiety (D). The strong antioxidant activity of MitoTEMPO is evident in (E). In addition to the CellROX images (left column), the DAPI nuclear stain (middle column) and merged DAPI-CellRox images (right column) are shown. Scale bar represents 20 μ m.




Figure 6. Quantification of mean fluorescence intensity signal from A β -induced ROS signal (see Figure 5) in N2a neuronal cells treated with 1 μ M exogenous A β . The effect of SLF, SLF^{dm}, and MitoTEMPO co-addition on the A β -induced ROS signal of A β -treated N2a cells is given by the green, orange, and blue bars, respectively, and is compared to the +A β group. Statistical analysis of fluorescence intensity by one-way ANOVA gives * $p < 0.01$, ** $p < 0.001$, $n = 3$. Error bars represent the standard error as described in the Methods section.




Figure 7. Super-resolution structured illumination (SIM) images of intraneuronal A β stained with the amyloid dye FSB (green). In all images, MC65 neuronal cells were stained with propidium iodide (red). No FSB signal is observed for cells grown in the absence of APP induction (+TC, panel A). For cells induced for APP expression, a large intracellular A β accumulation is apparent (green signal, panel B), which leads to a distortion of the nuclear membrane (yellow arrow). When SLF is included in the APP-induced MC65 culture, the A β stain signal is greatly reduced (C). Scale bar represents 1 μ m.

2.5. SLF Decreases the Formation of Intracellular A β O in a Human Neuroblastoma Cell Line Overexpressing the Amyloid Precursor Protein Detected by the Oligomer-Specific Antibody

The oligomer-specific antibody A11 provides a powerful tool to detect the presence of A β in its toxic, oligomeric state [36,37]. A11 also reacts with oligomeric forms of other amyloidogenic peptides such that it recognizes a conformation specific to pathogenic misfolded proteins. To specifically probe the effect of SLF on oligomeric A β (A β O), MC65 neurons overexpressing the APP protein were cultured for 24 hours in the presence of SLF or vehicle, stained with A11 antibody, and examined by confocal microscopy (Figure 8). In the absence of APP induction, no A11 signal is detected (Figure 8A). Upon induction of the A β precursor, a clear perinuclear signal for the A11 antibody is evident (green staining, Figure 8B), which shows that much of the accumulated intracellular A β is in the oligomeric state. As shown in Figure 8C, SLF treatment of APP-induced MC65 cells effectively

removes all A11 staining relative to the non-induced control. SLF lacking its catalytic antioxidant functionality (SLF^{dm}) is less efficient in blocking A β O accumulation (Figure 8D), although it performs better than the nitroxide antioxidant alone (Figure 8E). Quantification of the green fluorescent signal of the anti-A β O antibody from confocal images of cultured cells is shown in Figure 9A. SLF shows a large decrease (about seven-fold) in fluorescence intensity from the anti-A β O antibody versus cells treated with vehicle. SLF^{dm} and MitoTEMPO showed approximately a three-fold decrease and about a five-fold decrease in A11 intensity versus treatment with the vehicle alone, respectively (Figure 9A). The intensity of A β staining in APP-induced cells without protective treatment was highly variable, which is indicated by the error bars in Figure 9. This can be attributed to uneven localization and aggregation and trafficking patterns of A β within the highly stressed cells.




Figure 8. SLF greatly reduces the presence of intraneuronal oligomeric A β (A β O) in MC65 cells overexpressing APP. The presence of A β O was detected by the oligomer-specific antibody A11 (indicated by green Cy2 signal) in MC65 cells examined by confocal microscopy. In the absence of APP induction, there is no detection of intraneuronal A β O (A). With overexpression of APP, A β O staining is clearly evident (B). Addition of SLF to MC65 cells overexpressing APP results in a dramatic decrease in A β O (C). Relative to SLF, the ability of diamagnetic SLF to reduce A β O is markedly less (D), which suggests that ROS promotes A β generation and/or A β O formation. Row (E) shows that MitoTEMPO attenuates A β O only partially, which is consistent with the notion of the synergistic action of SLF (conformational effects and targeted antioxidant). In addition to the Cy2 images (left column), images for the DAPI nuclear stain (middle column) and merged DAPI-Cy2 images (right column) are shown. The scale bar represents 20 μ m.




Figure 9. Quantification of the mean fluorescence intensity signal in confocal images of MC65 cells stained with the anti-A β O antibody A11 (panel A, see Figure 8) or the generic anti-A β antibody 4G8 (for total A β , panel B, see Figure 10). The effect of SLF, SLF^{dm}, and MitoTEMPO co-addition on the intracellular accumulation of A β in APP-induced MC65 cells is given by the green, orange, and blue bars, respectively, and is compared to the –TC vehicle control. Statistical analysis of fluorescence intensity by one-way ANOVA gives * $p < 0.01$, ** $p < 0.001$, $n = 3$. Error bars represent the standard error, which is described in the Methods section.

2.6. SLF Decreases Accumulation of Total Intracellular A β in a Human Neuroblastoma Cell Line Overexpressing the Amyloid Precursor Protein

Intracellular A β exists as a dynamic mix of soluble oligomers of various sizes with the small intracellular soluble oligomers considered the most toxic form of A β [38]. In order to test whether SLF decreases the total A β load within the cells, MC65 neurons expressing APP protein were stained with the 4G8 antibody, which recognizes all conformational states of the peptide. Induced (–TC) cells were treated with vehicle or SLF for 24 hours, stained with the 4G8 antibody for total A β levels, and imaged by confocal microscopy (Figure 10). As shown in Figure 10C, SLF substantially lowers total A β relative to the vehicle control (Figure 10B). Therefore, the ability of SLF to lower A β O levels (Figure 8) can, in part, be attributed to improved cellular clearance of the peptide generated by APP overexpression. Similarly to their effects on A β O levels, SLF^{dm} and MitoTEMPO treatment also lower total A β levels, but to a lesser extent than the bifunctional SLF. Quantification of 4G8 intensity (Figure 8, green signal) is shown in Figure 9B. Regarding their effects on total A β , SLF^{dm} outperforms MitoTEMPO, which may indicate that antioxidant functionality is more significant in modulating the formation of A β O while the clearance of total A β benefits more from the conformational effects caused by the docking moiety of SLF.

2.7. SLF Decreases Uptake of A β in Cultured Neurons Treated with Exogenous A β

We sought to investigate whether SLF can attenuate intracellular aggregation of exogenous A β in N2a neuronal cultures grown in the presence of 1 μ M A β . We assessed intracellular uptake of exogenous A β by measuring the fluorescence intensity of FSB in N2a cells treated with A β . As shown in Figure 11, confocal imaging clearly shows a cytoplasmic uptake of exogenous A β as evident by the bright green dots around the nucleus and in the cytoplasmic space (Figure 11A). The cytoplasmic distribution of the exogenous A β after uptake into the cell matches that of the endogenous A β of the MC65 cells post-APP overexpression (green accumulation protruding into the nuclear membrane shown by super-resolution imaging, Figure 7B). The effect of SLF on A β uptake was determined by including 2 μ M of SLF in the culture medium at the time of the addition of 1 μ M A β . As shown in Figure 11B, SLF decreases the FSB staining in N2a cells treated with A β , which suggests that SLF either inhibits A β uptake and/or promotes the peptide's metabolism within the cell.




Figure 10. SLF reduces the presence of total intraneuronal A β in MC65 cells overexpressing APP. The presence of A β was detected by the conformational-independent antibody 4G8, which recognizes all forms of A β . Bound 4G8 antibody is indicated by the green Cy2 signal in the MC65 cells examined by confocal microscopy. In the absence of APP induction, there is only slight staining by 4G8 (A). With overexpression of APP, A β staining is clearly evident (B). Addition of SLF to MC65 cells overexpressing APP results in a dramatic decrease in the total A β (C). Relative to SLF, the ability of diamagnetic SLF to reduce total A β is markedly less (D), which suggests that ROS promotes A β generation and/or inhibits A β clearance. Row (E) shows that MitoTEMPO attenuates total A β slightly better than SLF^{dm}, which supports the notion that ROS levels significantly affect A β metabolism. The left column is the Cy2 stain, the middle column is the DAPI nuclear stain, and the right column is a merging of the first two columns. Scale bar represents 20 μ m.




Figure 11. Confocal microscopy of N2a cells stained with the amyloid dye FSB with exogenous A β treatment. Panel (A) shows cells stained with FSB 24 hours after the addition of 1 μ M A β . Panel (B) shows cells that were treated with 1 μ M A β + 2 μ M SLF and stained with FSB 24 hours later. Bright green dots in (A) show a cytoplasmic, perinuclear distribution indicative of intracellular uptake of exogenous A β . Scale bars represent 10 μ m.

2.8. SLF Decreases the Presence of A β O in Cultured Neurons Treated with Exogenous A β

The ability of SLF to specifically reduce oligomeric A β in N2a neurons treated with exogenous A β was assessed by measuring the fluorescence intensity of the A11 antibody in cells with and without SLF treatment. Significantly elevated fluorescence intensity is indicative of the formation of A β oligomers and is noted in the neurons treated with A β in the absence of SLF (Figure 12A) while the fluorescence intensity was significantly reduced in neuronal cultures treated with A β in the presence of SLF (Figure 12B). To further explore the role of the two moieties of the SLF compound, we compared the isolated effect of the nitroxide component (MitoTEMPO) versus the fluorene component (SLF^{dm}) on intracellular A β O levels resulting from exogenous A β addition. Although neuronal cells treated with SLF^{dm} (Figure 12D) or MitoTEMPO (Figure 12E) display a reduction in A β O accumulation, the effect is not as pronounced as that of the SLF treatment. Quantification of the fluorescence intensity shows SLF reduces intracellular A β aggregation at about seven-fold compared to untreated cells, about two-fold compared to cells treated with MitoTEMPO, and about three-fold compared to cells treated with a diamagnetic version of the fluorene compound (Figure 13).




Figure 12. SLF blocks A β O formation of exogenous A β added to cultured N2a neurons. Shown are confocal images of N2a cells stained with the oligomer-specific antibody A11 (green signal). A control with only the DMSO vehicle added (no A β) is shown in row (A). Row (B) demonstrates that exogenous A β is readily taken up by neurons and adopts the oligomer-specific conformation. Row (C) shows the accumulation of imported A β O is blocked by SLF. The significance of the nitroxyl antioxidant functionality in blocking oligomer formation is demonstrated by the diminished ability of SLF^{dm} to inhibit intracellular A β O accumulation (row D). Similarly, the antioxidant activity of MitoTEMPO lowers A β O accumulation (row E), but not as effectively as the A β -targeted SLF compound. The left column is the Cy2 stain, the middle column is the DAPI nuclear stain, and the right column is the merging of the first two columns. Scale bar represents 20 μ m.




Figure 13. Quantification of mean fluorescence intensity signal in N2a neuronal cells (see Figure 12) treated with exogenous A β (1 μ M in culture) and stained with anti-A β O antibodies (A11). The effect of SLF, SLF^{dm}, and MitoTEMPO co-addition on intracellular accumulation of A β is given by the green, orange, and blue bars, respectively, and is compared to the +A β group. Statistical analysis of fluorescence intensity by one-way ANOVA gives * $p < 0.01$, ** $p < 0.001$, $n = 3$. Error bars represent the standard error, which is described in the Methods section.

3. Discussion

The amyloid beta (A β) peptide is well known for its intrinsically disordered secondary structure and high propensity to form aggregates of various sizes [39–41]. While the monomeric form of A β is generally considered an antioxidant, metal chelator, and synaptic plasticity enhancer, it is well accepted that the oligomerization of A β leads to toxic effects [42,43]. Generated first as a monomer, the oligomerization of A β starts intracellularly, which leads to early pathologic oligomeric A β species that disrupt neuronal function and lead to decreased cognition and a decline in memory [44]. Disrupting the formation of A β O at the intracellular level is, therefore, crucial for targeting AD pathology during the early stages before permanent damage occurs.

Oxidative stress remains a common factor connecting several markers for AD pathology both at the onset and during the progression of disease. Therefore, antioxidant activity provides an attractive component for multi-target anti-AD candidates [12]. The role of A β in increasing oxidative stress, especially due to its metal binding sites (particularly for Cu²⁺), and its ability to reduce Cu²⁺ and Fe³⁺ to Cu⁺ and Fe²⁺ (generating superoxide anions) have been amply documented using various methods to detect reactive oxidative species [30–32]. Therefore, agents capable of localizing anti-ROS activity at A β can greatly increase potency. In order to minimize interference with cellular ROS-dependent signaling and endogenous ROS protection pathways, it is becoming increasingly clear that high potency compounds will be especially beneficial to antioxidant approaches [45]. In addition to localizing antioxidant activity at A β , the nitroxide is a highly efficient ROS scavenger that can perform in a catalytic fashion [24,25].

We have previously reported on the bifunctional ability of SLF to scavenge ROS, decrease A β aggregation, and alter the conformation of oligomeric A β in vitro [20–22,46]. In this study, we investigate how the bifunctionality of SLF can both affect the aggregation dynamics of A β and, through the SLF's nitroxide moiety, maintain ROS homeostasis in cultured neurons. We sought to investigate to what extent the rescued cell survival afforded by SLF is due to its nitroxide antioxidant, fluorene conformational modulator, or the combination of both. The two functional components were evaluated independently by employing a diamagnetic version of SLF (SLF^{dm}) that lacks the nitroxyl functional group as well as a potent nitroxyl-based antioxidant (MitoTEMPO) that lacks the

ability to engage A β and modulate its structure/oligomerization. In neurons challenged by either the overproduction of A β (MC65 cells) or by exogenous A β addition (N2a cells), SLF provides superior protection compared to SLF^{dm} and MitoTEMPO. With regard to cellular protection, the nitroxide component (represented by the MitoTEMPO treatment) affords greater protection against A β addition when compared to SLF^{dm}. We propose SLF has the unique capacity to increase neuronal survival in the face of an A β challenge by simultaneously decreasing A β oligomerization and A β -induced oxidative stress. There is ample evidence supporting the presence of a positive feedback cascade between A β oligomer formation, ROS generation, and A β production with any one of these processes stimulating the rates of the other two, which results in a highly injurious cycle that ultimately leads to neuronal death [16,47,48]. While the two SLF moieties separately act on the specific tasks of oligomerization and ROS scavenging, their results affect each other in the sense that decreased ROS leads to less A β O production and less A β results in less oxidative stress.

We then probed the distinct functionalities of SLF by separately investigating its effects on A β levels and ROS scavenging. First, we used super resolution microscopy to image the intracellular A β load in MC65 cells with and without SLF treatment. The FSB-stained cells show a large accumulation of A β . This should be evaluated as total A β since FSB stains various forms of amyloid assembly. The high-resolution image reveals a clear perinuclear distribution of A β with an apparent distortion of the nuclear membrane. The significance of this distribution in the etiology of AD remains to be investigated. When the APP-induced MC65 cells are treated with SLF, the FSB signal is dramatically reduced. This indicates that SLF not only protects against A β toxicity but also affects A β metabolism within the cell by decreasing amyloidogenic processing and/or increasing A β clearance. Our previous studies [20–22] showing that SLF converts A β O into smaller, more stable oligomers may provide a thermodynamic explanation for the enhanced peptide clearance. In this regard, further imaging studies directed towards candidate pathways for SLF-enhanced clearance will be very useful.

To address whether SLF affects the levels of oligomeric A β specifically, we carried out confocal analyses of MC65 cells stained with the oligomer-specific antibody A11 as well as the 4G8 antibody, which recognizes all forms of A β . Similar to the FSB results described above, untreated MC65 cells induced to overexpress APP reveal a high level of A β that appears to outline the nuclear envelope within the cytoplasm. SLF decreases the levels of intracellular A β O as well as total A β significantly more than either SLF^{dm} or MitoTEMPO. Similarly, treatment with MitoTEMPO also decreases intracellular A β O content, albeit to a lesser extent. Therefore, while overall protection correlates strongly with the nitroxyl ROS scavenging, the conformational targeting by SLF and SLF^{dm} enhances A β clearance over antioxidant activity alone. Nevertheless, the decreased A β levels found in MC65 cells with MitoTEMPO treatment align with previous studies showing that oxidative stress promotes intracellular accumulation of A β [49–51]. A less aggressive amyloid model was also used to evaluate the differential effect of the agents on intracellular A β O accumulation by treating N2a neurons with exogenous A β and then staining with the A11 antibody. Confocal images show A β is imported into the neurons. However, the amount is substantially less in the presence of SLF. The question of whether SLF is inhibiting A β uptake and/or enhancing its clearance remains to be studied.

With respect to the ROS scavenging ability of SLF, our measurements show SLF is a much more efficient scavenger compared to either of its two components taken separately. While SLF containing both the fluorene and nitroxide components significantly decreases oxidative stress, SLF^{dm} has only a mild effect in both the endogenous and exogenous A β models. However, the MitoTEMPO treatment shows differing results depending on the situation. Although MitoTEMPO affords less protection than SLF in both cases, it more efficiently protects N2a cells from exogenous A β -induced ROS. This might indicate that under a milder A β insult, the ROS levels can be strongly attenuated without structural engagement of the A β .

These findings support a synergistic effect of the two components of SLF in counteracting both the conformational toxicity of A β and its promotion of ROS scavenging, propelling SLF forward as a potential therapeutic candidate for further studies on early progression of AD. Previous findings

indicate that the accumulation of A β induces oxidative stress and oxidative stress induces the accumulation of A β [49]. In light of this link, we postulate the unique bifunctionality of SLF makes it an ideal candidate to pursue as a potentially effective therapy against AD development and progression.

4. Materials and Methods

4.1. Materials

Spin-labeled fluorene (SLF) and diamagnetic spin-labeled fluorene (SLF^{dm}) were synthesized as previously described [52]. Amyloid beta (A β) peptide (1–40) was purchased from EZBiolab Inc., Carmel, IN, USA. Hoechst Blue 3342 nuclear stain was purchased from Thermo Fisher, Waltham, MA, USA. CellRox (Deep Red; $\lambda_{\text{ex}}/\lambda_{\text{em}}$ 640/665 nm) was purchased from Life Technologies, Waltham, MA, USA. (*E,E*)-1-Fluoro-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (FSB) amyloid stain was purchased from Calbiochem, MilliporeSigma, Burlington, MA, USA. Oligomer A11 polyclonal antibody was purchased from Thermo Fisher, Waltham, MA, USA. The 4G8 anti β -Amyloid 17–24 antibody was purchased from BioLegend, San Diego, CA, USA. The cyanine conjugate (Cy2) donkey anti-goat, secondary antibody was purchased from Jackson Immuno Research, West Grove, PA, USA. The Opti-Minimal Essential Medium (OPTIMEM) was purchased from Invitrogen/Life Technologies. PBS pH 7.4 (-Calcium Chloride, -Magnesium Chloride), Opti-MEM[®] I Reduced Serum Medium (no phenol red), DMEM (Dulbecco's modified Eagle's medium +4.5 g/L Glucose, L-Glutamine, and 110 mg/L Sodium Pyruvate), and Fetal Bovine Serum (FBS) were purchased from Gibco (Carlsbad, CA, USA). 35 mm Glass Bottom Dishes (No. 1.5) were purchased from MatTek, Ashland, MA, USA. Trypan Blue Solution (0.4%) was purchased from Sigma-Aldrich, St. Louis, MO, USA.

4.2. Cell Line Model Over-Expressing Intracellular A β

We used MC65 cells, a neuronal cell culture line that shows intracellular accumulation of A β [29,33,53,54]. The MC65 cells are derived from a human neuroblastoma line with conditional expression of the carboxyl-terminal 99 residues of the amyloid- β precursor protein (APP-C99) under the negative regulation of the suppressor tetracycline (TC) in the culture medium. Proteolysis of APP-C99 by the cellular γ and β secretases generates A β . Intracellular A β is known to start to accumulate as early as 4 h after TC removal with maximal levels at 24 h. While cell death 3 days after removal of TC was shown to be due to the intracellular accumulation of A β O rather than to the small amounts of secreted A β [33], fluorescence microscopy analyses of cells was done at 24 h so that effects of oxidative stress can be acutely attributed to A β . However, the MTT assay for cell viability was done at 3 days to allow for the observation of changes in cell morphology. The MC65 cells were cultured in a 75 mL flask in a culture medium composed of a mixture of 50% Dulbecco's Modified Eagle Medium supplemented with 4.5 mg/mL D-glucose, non-essential amino acids, 1 mM sodium pyruvate, and 10% (*v/v*) heat-inactivated fetal bovine serum, supplemented with 0.1 mg/mL tetracycline, 50 IU/mL penicillin, and 50 μ g/mL streptomycin. The cultures reached 80% confluence after 24 h. At this point, the cells were harvested and the trypan blue exclusion test was used to determine the count of viable cells for calculations of cell density. Cells were then seeded at a density of 2.5×10^5 cells/well in 96-well plates for the MTT viability assay and in glass bottom culture dishes for the other experiments. Expression of APPC99 in MC65 cells was induced by removing TC from cell culture medium and cells were treated with various treatments described for each experiment. To examine the effects of SLF on exogenous A β , we used the Neuro-2a mouse neuroblastoma cell line (N2a). The N2a cells were cultured in the same culture media as the MC65 cells (only without TC in the culture media) in a 75 mL culture flask and reached 80% confluence after 12 h. They were then harvested and processed similarly to MC65 cells. Exogenous A β was prepared as described in Section 4.3 and was added to a final concentration of 1 μ M in +/– for the same treatments as those of the MC65 cells. For both cell lines, we cultured cells from three different passages on different days. For the fluorescence intensity quantification, we selected three clusters of 30 cells from each

image to normalize for the cell number and background intensity. We then used Image J to quantify fluorescence intensity for the CellRox and Cy2 channels.

4.3. Preparation of Amyloid-Beta Peptide Solution

A β solution was prepared as previously described [20,21,23]. The A β peptide was reconstituted in hexa-fluoro-isopropanol (HFIP) and incubated at room temperature on a shaker for 48–72 h until it became clear. Aliquots of 0.1 mg A β were placed in a SpeedVac to remove the HFIP and the resulting monomeric peptide film was stored at -80 °C. Immediately before use, the A β peptide film was reconstituted in 10 μ L fresh DMSO for a stock solution of 1 mM A β . The A β solution diluted to a final concentration of 1 μ M was co-added to the N2a cultured cells treated with either vehicle or 2 μ M final concentration of SLF, mitoTEMPO, or diamagnetic fluorene (SLF^{dm}). Since A β starts to aggregate almost immediately after the addition to the culture media, we introduced the A β solution to the N2a cell culture simultaneously with the compounds and incubated at 37 °C for 24 h to let A β oligomerize in situ. Although the concentration of the intracellular A β is not known, it is likely higher than that of the 1 μ M A β added to the culture media. We choose the 1:2 A β :SLF molar ratio since, at these concentrations, A β is expected to be fully saturated with SLF [21,22].

4.4. Cell Viability Assay

Cytotoxicity in N2a and MC65 cells cultured and treated as described in Section 4.2 was determined using counts of viable cells 72 h after treatment based on the MTT assay (tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), which was described previously by Maezawa et al., 2007. Both N2a and MC65 cells were plated at a density of 2.5×10^5 cells/well in a 96-well plate in 200 μ L in the same medium described in Section 4.2. The A β solution was prepared in phenol red-free (OPTIMEM) and fetal bovine serum-free media as described in Section 4.3, then added to the N2a cell cultures at final concentrations of 1 μ M for A β and 2 μ M for SLF, SLF^{dm}, and MitoTEMPO. The MC65 cells were cultured in the same conditions in the presence and absence of TC at 1 μ g/mL. The compounds were added to the cultures at 2 μ M for SLF, SLF^{dm}, and MitoTEMPO for 9 wells and 3 rows. After 24 h of incubation, 150 μ L media was removed and 5.5 μ L of 2.5 mg/mL MTT (thiazolyl blue compound) was added to each well to a final concentration of 0.25 mg/mL. After 2 h incubation at 37 °C, 100 μ L of solubilization buffer (0.1 N HCL in isopropanol) was added to each well and the plates were placed on a shaker at room temperature until blue crystals are dissolved. The plate was read on the plate reader at 560 nm for MTT and 630 nm for baseline subtraction. Cell viability was expressed as the percentage of viable cells.

4.5. Cell Culture for the Detection of Intracellular A β by Super-Resolution Structured Illumination Imaging

The MC65 neuronal cells were washed extensively and plated at a density of 3.5×10^5 cells/well over 18/18 mm #1.5 Fisherbrand Microscope Cover Glasses in OPTIMEM containing 50 IU/mL penicillin and 50 μ g/mL streptomycin without serum and without TC. The neuronal cells were treated with 10 μ M SLF or with the vehicle. The control cells were plated in OPTIMEM with TC. After 24 h of incubation at 37 °C, the cultures were washed in PBS pH 7.4 for 15 min \times 3 to discard any extracellular A β , fixed in 4% paraformaldehyde, and stained for 10 min in 5 μ M (*E,E*)1-fluoro-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (FSB) amyloid stain. After washing in PBS pH 7.4 for 1 h \times 3, the cover glasses were mounted with Vectashield Mounting Medium with Propidium Iodide (PI) over microscope slides [34].

4.6. Super-Resolution Structured Illumination Imaging of FSB-Stained Intracellular A β

Super-resolution structured illumination (SIM) imaging was used to obtain images of FSB-stained A β inclusions (green) in MC65 cells overexpressing APP protein, which were grown in the presence (+TC) and absence (–TC) of an inducible repressor. Images were taken using a Deltavision OMX v2.0, (Applied Precision, LLC, Issaquah, WA, USA) super-resolution, wide-field, Structured-Illumination

fluorescence Microscope (SIM) that uses a 60 \times magnification and 1.40 NA objective lens immersed in 1.514 refractive index oil. The FSB/PI staining was viewed using excitation lasers at $\lambda_{\text{ex}} = 405$ nm and 488 nm, respectively. The Z-stacked images were reconstructed using the deconvolution software SoftWoRx version 4.1 (GE Healthcare, Marlborough, MA, USA). Reconstructed images were processed using Volocity 5.5.1 (Perkin Elmer Inc., Waltham, MA, USA) to generate 3-D images.

4.7. Immunofluorescence Staining for the Accumulation of Intracellular A β

MC65 and N2a neurons were cultured on cover slips, treated as described in Section 4.3, incubated at 37 °C for 24 h, washed in untreated culture media for 15 min \times 3 to discard any extracellular A β , and fixed in 4% paraformaldehyde. To detect the accumulation of intracellular A β oligomers, the MC65 and N2a cells were then stained with anti-A β oligomer A11 antibodies (1:2000) overnight at 4 °C, and then with Cy2 fluorescent secondary antibodies for 3 h at room temperature. To detect the accumulation of total intracellular A β , the MC65 cells were stained with anti-A β antibodies 4G8 (1:1000) overnight at 4 °C followed by Cy2 fluorescent secondary antibodies for 3 h at room temperature. Additionally, to detect intracellular uptake of A β , the N2a cells treated with exogenous A β (1 μ M) in the presence and/or absence of SLF (2 μ M) for 24 h were stained for 10 min in 5 μ M amyloid dye FSB ((E,E)-1-fluoro-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene). After staining, cells were washed extensively in culture media \times 3, fixed in 4% paraformaldehyde for 10 min and imaged [34,35,54].

4.8. Detection of Intracellular A β Oligomers, Total A β , and Intracellular Uptake of A β by Confocal Microscopy

Fixed cells were imaged with an Olympus Fluoview FV1000 spectrum confocal microscope (Life Science Solutions, Center Valley, PA, USA). Each individual field was imaged using an \times 40 objective. Single plane confocal scans of the cultured MC65 neuronal cells and N2a cells areas were taken via sequential scanning mode. Fluorescence intensity comparison was then used to determine differences between the accumulations of intracellular A β under various treatments.

4.9. Detection of the Intracellular Oxidative Stress Signal by Confocal Microscopy

Treated and control MC65 and N2a cells were gently washed with untreated culture medium and incubated for 30 min with the ROS detection reagent CellROX, which is a fluorogenic probe that when oxidized develops a red fluorescent signal seen around the nuclei of unprotected cells. At 20 min, the cells were treated for the remaining 10 min with a Hoechst Blue 3342 nuclear stain, gently washed for 15 min \times 3 with untreated culture medium, and imaged immediately. The images of CellROX staining were collected on an Olympus FV1000 spectrum confocal microscope. Each individual field was imaged using an \times 40 objective. Single plane confocal scans of the cultured neuronal cell areas were taken through the sequential scanning mode using diode excitation lasers of 653 nm for CellROX Deep Red ($\lambda_{\text{exc}}/\lambda_{\text{em}} = 640/665$ nm) and 559 nm excitation laser for Cy2 ($\lambda_{\text{exc}}/\lambda_{\text{em}} = 492/510$ nm). Intensity comparison of the ROS signal was then performed to compare A β -induced oxidative stress.

4.10. Statistical Analysis and Quantification of Immunohistochemical Staining

Statistical significance between groups of cells under different treatments was determined by an ordinary one-way ANOVA test using GraphPad Prism version 7.0c for MAC OS X, GraphPad Software, La Jolla, CA, USA, where *p* value from the ANOVA is reported as a result of the Brown-Forsythe test and is considered significant if <0.05 . All data were expressed as the mean \pm SEM from multiple measurements. For each measured condition in MTT assays, $n = 12$. For fluorescence intensity measurements, $n = 3$, and multiple ROIs were measured from groups of 30 cells with 3 areas of each image obtained from 3 different dishes of cells for each group. Each dish was cultured from a different stock of a different passage (12–14).

The images of the CellRox and A β -stained cells were transformed to 8-bit gray scale and fluorescence intensity was analyzed with Image J, FIJI (version 2.0.0-rc-68/1.52e, open-source platform

for biological image analysis) for MAC OS X, using the particle analysis function [55]. One-way ANOVA followed by a Tukey multiple comparisons test was performed to compare mean fluorescence intensity between the treatment groups using the GraphPad Prism version 7.0c for MAC OS X, GraphPad Software, La Jolla, CA, USA. Triplicate measurements were done in 3 randomly selected areas of each of the cell culture fields with a background correction. All data were expressed as the mean \pm SEM.

Author Contributions: Conceptualization, S.H., L.-W.J. and J.C.V.; Methodology, S.H. and J.C.V.; Validation, S.H.; Formal Analysis, S.H., Q.G., S.W.-H. and J.C.V.; Investigation, S.H. and R.A.; Resources, T.K., I.M., Q.G., L.-W.J., and J.C.V.; Writing—Original Draft Preparation, S.H., R.A., and J.C.V.; Writing—Review & Editing, S.H., R.A., and J.C.V.; Visualization, S.H., Q.G. and S.W.-H.; Supervision, J.C.V.; Funding Acquisition, S.H. and J.C.V.

Funding: This work was supported by a STAIR Award from the University of California Davis to J.C.V. and, in part, with funding from the National Institutes of Health (grant P30 AG010129 to J.C.V.). S.H. was supported by the National Institute on Aging of the National Institutes of Health under the Award Number T32AG050061. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health. T.K. acknowledges the support of grant GINOP-2.3.2-15-2016-00049.

Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References

1. Du, H.; Guo, L.; Yan, S.; Sosunov, A.A.; McKhann, G.M.; Yan, S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 18670–18675. [[CrossRef](#)] [[PubMed](#)]
2. Du, H.; Yan, S.S. Mitochondrial permeability transition pore in Alzheimer's disease: Cyclophilin D and amyloid beta. *Biochim. Biophys. Acta* **2010**, *1802*, 198–204. [[CrossRef](#)] [[PubMed](#)]
3. Moreira, P.I.; Carvalho, C.; Zhu, X.; Smith, M.A.; Perry, G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. *Biochim. Biophys. Acta* **2010**, *1802*, 2–10. [[CrossRef](#)] [[PubMed](#)]
4. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer's disease. *Nat. Rev. Neurosci.* **2007**, *8*, 499–509. [[CrossRef](#)] [[PubMed](#)]
5. Kienlen-Campard, P.; Miolet, S.; Tasiaux, B.; Octave, J.N. Intracellular amyloid- β 1-42, but not extracellular soluble amyloid- β peptides, induces neuronal apoptosis. *J. Biol. Chem.* **2002**, *277*, 15666–15670. [[CrossRef](#)] [[PubMed](#)]
6. Knobloch, M.; Konietzko, U.; Krebs, D.C.; Nitsch, R.M. Intracellular A β and cognitive deficits precede β -amyloid deposition in transgenic arcA β mice. *Neurobiol. Aging* **2007**, *28*, 1297–1306. [[CrossRef](#)] [[PubMed](#)]
7. Takahashi, R.H.; Nagao, T.; Gouras, G.K. Plaque formation and the intraneuronal accumulation of β -amyloid in Alzheimer's disease. *Pathol. Int.* **2017**, *67*, 185–193. [[CrossRef](#)] [[PubMed](#)]
8. Zhang, Y.; McLaughlin, R.; Goodyer, C.; LeBlanc, A. Selective cytotoxicity of intracellular amyloid β peptide(1–42) through p53 and Bax in cultured primary human neurons. *J. Cell Biol.* **2002**, *156*, 519–529. [[CrossRef](#)] [[PubMed](#)]
9. Oddo, S.; Caccamo, A.; Smith, I.F.; Green, K.N.; LaFerla, F.M. A dynamic relationship between intracellular and extracellular pools of Abeta. *Am. J. Pathol.* **2006**, *168*, 184–194. [[CrossRef](#)] [[PubMed](#)]
10. Mao, P. Oxidative Stress and Its Clinical Applications in Dementia. *J. Neurodegener. Dis.* **2013**, *2013*, 1–15. [[CrossRef](#)] [[PubMed](#)]
11. Persson, T.; Popescu, B.O.; Cedazo-Minguez, A. Oxidative stress in Alzheimer's disease: Why did antioxidant therapy fail? *Oxid. Med. Cell. Longev.* **2014**, *2014*, 1–11. [[CrossRef](#)] [[PubMed](#)]
12. Rosini, M.; Simoni, E.; Milelli, A.; Minarini, A.; Melchiorre, C. Oxidative stress in Alzheimer's disease: Are we connecting the dots? *J. Med. Chem.* **2014**, *57*, 2821–2831. [[CrossRef](#)] [[PubMed](#)]
13. Bradley, M.A.; Xiong-Fister, S.; Markesbery, W.R.; Lovell, M.A. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. *Neurobiol. Aging* **2012**, *33*, 1034–1044. [[CrossRef](#)] [[PubMed](#)]
14. Ansari, M.A.; Scheff, S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. *J. Neuropathol. Exp. Neurol.* **2010**, *69*, 155–167. [[CrossRef](#)] [[PubMed](#)]

15. Kuhla, B.; Haase, C.; Flach, K.; Luth, H.J.; Arendt, T.; Munch, G. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. *J. Biol. Chem.* **2007**, *282*, 6984–6991. [[CrossRef](#)] [[PubMed](#)]
16. Tabner, B.J.; El-Agnaf, O.M.; German, M.J.; Fullwood, N.J.; Allsop, D. Protein aggregation, metals and oxidative stress in neurodegenerative diseases. *Biochem. Soc. Trans.* **2005**, *33*, 1082–1086. [[CrossRef](#)] [[PubMed](#)]
17. Pohanka, M. Alzheimer's disease and oxidative stress: A review. *Curr. Med. Chem.* **2014**, *21*, 356–364. [[CrossRef](#)] [[PubMed](#)]
18. Hernandez-Zimbron, L.F.; Luna-Munoz, J.; Mena, R.; Vazquez-Ramirez, R.; Kubli-Garfias, C.; Cribbs, D.H.; Manoutcharian, K.; Gevorkian, G. Amyloid- β peptide binds to cytochrome C oxidase subunit 1. *PLoS ONE* **2012**, *7*, e42344. [[CrossRef](#)] [[PubMed](#)]
19. Reddy, P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: Implications for mitochondrially targeted antioxidant therapeutics. *J. Biomed. Biotechnol.* **2006**, *2006*, 1–13. [[CrossRef](#)] [[PubMed](#)]
20. Altman, R.; Ly, S.; Hilt, S.; Petrlova, J.; Maezawa, I.; Kalai, T.; Hideg, K.; Jin, L.W.; Laurence, T.A.; Voss, J.C. Protective spin-labeled fluorenes maintain amyloid beta peptide in small oligomers and limit transitions in secondary structure. *Biochim. Biophys. Acta* **2015**, *1854*, 1860–1870. [[CrossRef](#)] [[PubMed](#)]
21. Petrlova, J.; Kalai, T.; Maezawa, I.; Altman, R.; Harishchandra, G.; Hong, H.S.; Bricarello, D.A.; Parikh, A.N.; Lorigan, G.A.; Jin, L.W.; et al. The influence of spin-labeled fluorene compounds on the assembly and toxicity of the A β peptide. *PLoS ONE* **2012**, *7*, e35443. [[CrossRef](#)] [[PubMed](#)]
22. Hilt, S.; Rojalín, T.; Viitala, T.; Koivuniemi, A.; Bunker, A.; Wachsmann-Hogiu, S.; Kálai, T.; Hideg, K.; Yliperttula, M.; Voss, J.C. Oligomerization Alters Binding Affinity between Amyloid Beta and a Modulator of Peptide Aggregation. *J. Phys. Chem. C* **2017**, *121*, 23974–23987. [[CrossRef](#)]
23. Hong, H.S.; Maezawa, I.; Budamagunta, M.; Rana, S.; Shi, A.; Vassar, R.; Liu, R.; Lam, K.S.; Cheng, R.H.; Hua, D.H.; et al. Candidate anti-A β fluorene compounds selected from analogs of amyloid imaging agents. *Neurobiol. Aging* **2010**, *31*, 1690–1699. [[CrossRef](#)] [[PubMed](#)]
24. Kalai, T.; Kuppasamy, M.L.; Balog, M.; Selvendiran, K.; Rivera, B.K.; Kuppasamy, P.; Hideg, K. Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity. *J. Med. Chem.* **2011**, *54*, 5414–5421. [[CrossRef](#)] [[PubMed](#)]
25. Venditti, E.; Scire, A.; Tanfani, F.; Greci, L.; Damiani, E. Nitroxides are more efficient inhibitors of oxidative damage to calf skin collagen than antioxidant vitamins. *Biochim. Biophys. Acta* **2008**, *1780*, 58–68. [[CrossRef](#)] [[PubMed](#)]
26. ElNaggar, A.C.; Saini, U.; Naidu, S.; Wanner, R.; Sudhakar, M.; Fowler, J.; Nagane, M.; Kuppasamy, P.; Cohn, D.E.; Selvendiran, K. Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. *Cancer Biol. Ther.* **2016**, *17*, 1107–1115. [[CrossRef](#)] [[PubMed](#)]
27. Wu, H.; Coble, V.; Vasalatiy, O.; Swenson, R.E.; Krishna, M.C.; Mitchell, J.B. An efficient synthesis of 3-(N-piperidinemethyl)-2,2,5,5-tetramethyl-1-oxy-3-pyrroline, a promising radioprotector for cancer radiotherapy. *Tetrahedron Lett.* **2014**, *55*, 5570–5571. [[CrossRef](#)] [[PubMed](#)]
28. Zarling, J.A.; Brunt, V.E.; Vallergera, A.K.; Li, W.; Tao, A.; Zarling, D.A.; Minson, C.T. Nitroxide pharmaceutical development for age-related degeneration and disease. *Front. Genet.* **2015**, *6*, 325. [[CrossRef](#)] [[PubMed](#)]
29. Hong, H.S.; Maezawa, I.; Yao, N.; Xu, B.; Diaz-Avalos, R.; Rana, S.; Hua, D.H.; Cheng, R.H.; Lam, K.S.; Jin, L.W. Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of A β oligomer-induced cytotoxicity. *Brain Res.* **2007**, *1130*, 223–234. [[CrossRef](#)] [[PubMed](#)]
30. Hureau, C.; Faller, P. A β -mediated ROS production by Cu ions: Structural insights, mechanisms and relevance to Alzheimer's disease. *Biochimie* **2009**, *91*, 1212–1217. [[CrossRef](#)] [[PubMed](#)]
31. Smith, D.G.; Cappai, R.; Barnham, K.J. The redox chemistry of the Alzheimer's disease amyloid beta peptide. *Biochim. Biophys. Acta* **2007**, *1768*, 1976–1990. [[CrossRef](#)] [[PubMed](#)]
32. Varadarajan, S.; Yatin, S.; Aksenova, M.; Butterfield, D.A. Review: Alzheimer's amyloid β -peptide-associated free radical oxidative stress and neurotoxicity. *J. Struct. Biol.* **2000**, *130*, 184–208. [[CrossRef](#)] [[PubMed](#)]
33. Maezawa, I.; Hong, H.S.; Wu, H.C.; Battina, S.K.; Rana, S.; Iwamoto, T.; Radke, G.A.; Pettersson, E.; Martin, G.M.; Hua, D.H.; et al. A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid- β oligomeric complexes. *J. Neurochem.* **2006**, *98*, 57–67. [[CrossRef](#)] [[PubMed](#)]

34. Sato, K.; Higuchi, M.; Iwata, N.; Saido, T.C.; Sasamoto, K. Fluoro-substituted and ¹³C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. *Eur. J. Med. Chem.* **2004**, *39*, 573–578. [[CrossRef](#)] [[PubMed](#)]
35. Flaherty, D.P.; Walsh, S.M.; Kiyota, T.; Dong, Y.; Ikezu, T.; Vennerstrom, J.L. Polyfluorinated Bis-styrylbenzene β -Amyloid Plaque Binding Ligands. *J. Med. Chem.* **2007**, *50*, 4986–4992. [[CrossRef](#)] [[PubMed](#)]
36. Kaye, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* **2003**, *300*, 486–489. [[CrossRef](#)] [[PubMed](#)]
37. Krishnan, R.; Goodman, J.L.; Mukhopadhyay, S.; Pacheco, C.D.; Lemke, E.A.; Deniz, A.A.; Lindquist, S. Conserved features of intermediates in amyloid assembly determine their benign or toxic states. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 11172–11177. [[CrossRef](#)] [[PubMed](#)]
38. Hubin, E.; van Nuland, N.A.; Broersen, K.; Pauwels, K. Transient dynamics of A β contribute to toxicity in Alzheimer's disease. *Cell. Mol. Life Sci.* **2014**, *71*, 3507–3521. [[CrossRef](#)] [[PubMed](#)]
39. Cleary, J.P.; Walsh, D.M.; Hofmeister, J.J.; Shankar, G.M.; Kuskowski, M.A.; Selkoe, D.J.; Ashe, K.H. Natural oligomers of the amyloid- β protein specifically disrupt cognitive function. *Nat. Neurosci.* **2005**, *8*, 79–84. [[CrossRef](#)] [[PubMed](#)]
40. Lesne, S.; Koh, M.T.; Kotilinek, L.; Kaye, R.; Glabe, C.G.; Yang, A.; Gallagher, M.; Ashe, K.H. A specific amyloid- β protein assembly in the brain impairs memory. *Nature* **2006**, *440*, 352–357. [[CrossRef](#)] [[PubMed](#)]
41. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Rowan, M.J.; Selkoe, D.J. Amyloid- β oligomers: Their production, toxicity and therapeutic inhibition. *Biochem. Soc. Trans.* **2002**, *30*, 552–557. [[CrossRef](#)] [[PubMed](#)]
42. Parihar, M.S.; Brewer, G.J. Amyloid- β as a modulator of synaptic plasticity. *J. Alzheimers Dis.* **2010**, *22*, 741–763. [[CrossRef](#)] [[PubMed](#)]
43. Pearson, H.A.; Peers, C. Physiological roles for amyloid β peptides. *J. Physiol.* **2006**, *575*, 5–10. [[CrossRef](#)] [[PubMed](#)]
44. Walsh, D.M.; Tseng, B.P.; Rydel, R.E.; Podlisny, M.B.; Selkoe, D.J. The oligomerization of amyloid β -protein begins intracellularly in cells derived from human brain. *Biochemistry* **2000**, *39*, 10831–10839. [[CrossRef](#)] [[PubMed](#)]
45. Bouayed, J.; Bohn, T. Exogenous antioxidants—Double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. *Oxid. Med. Cell. Longev.* **2010**, *3*, 228–237. [[CrossRef](#)] [[PubMed](#)]
46. Maezawa, I.; Zou, B.; Di Lucente, J.; Cao, W.S.; Pascual, C.; Weerasekera, S.; Zhang, M.; Xie, X.S.; Hua, D.H.; Jin, L.W. The Anti-Amyloid- β and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule. *J. Alzheimers Dis.* **2017**, *58*, 559–574. [[CrossRef](#)] [[PubMed](#)]
47. Zhang, L.; Zhao, B.; Yew, D.T.; Kusiak, J.W.; Roth, G.S. Processing of Alzheimer's amyloid precursor protein during H₂O₂-induced apoptosis in human neuronal cells. *Biochem. Biophys. Res. Commun.* **1997**, *235*, 845–848. [[CrossRef](#)] [[PubMed](#)]
48. Olivieri, G.; Hess, C.; Savaskan, E.; Ly, C.; Meier, F.; Baysang, G.; Brockhaus, M.; Muller-Spahn, F. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased β -amyloid secretion. *J. Pineal Res.* **2001**, *31*, 320–325. [[CrossRef](#)] [[PubMed](#)]
49. Misonou, H.; Morishima-Kawashima, M.; Ihara, Y. Oxidative stress induces intracellular accumulation of amyloid β -protein (A β) in human neuroblastoma cells. *Biochemistry* **2000**, *39*, 6951–6959. [[CrossRef](#)] [[PubMed](#)]
50. Paola, D.; Domenicotti, C.; Nitti, M.; Vitali, A.; Borghi, R.; Cottalasso, D.; Zaccheo, D.; Odetti, P.; Strocchi, P.; Marinari, U.M.; et al. Oxidative stress induces increase in intracellular amyloid β -protein production and selective activation of β I and β II PKCs in NT2 cells. *Biochem. Biophys. Res. Commun.* **2000**, *268*, 642–646. [[CrossRef](#)] [[PubMed](#)]
51. Shen, C.; Chen, Y.; Liu, H.; Zhang, K.; Zhang, T.; Lin, A.; Jing, N. Hydrogen peroxide promotes A β production through JNK-dependent activation of gamma-secretase. *J. Biol. Chem.* **2008**, *283*, 17721–17730. [[CrossRef](#)] [[PubMed](#)]
52. Kalai, T.; Petrlova, J.; Balog, M.; Aung, H.H.; Voss, J.C.; Hideg, K. Synthesis and study of 2-amino-7-bromofluorenes modified with nitroxides and their precursors as dual anti-amyloid and antioxidant active compounds. *Eur. J. Med. Chem.* **2011**, *46*, 1348–1355. [[CrossRef](#)] [[PubMed](#)]

53. Jin, L.W.; Shie, F.S.; Maezawa, I.; Vincent, I.; Bird, T. Intracellular accumulation of amyloidogenic fragments of amyloid- β precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. *Am. J. Pathol.* **2004**, *164*, 975–985. [[CrossRef](#)]
54. Maezawa, I.; Hong, H.S.; Liu, R.; Wu, C.Y.; Cheng, R.H.; Kung, M.P.; Kung, H.F.; Lam, K.S.; Oddo, S.; Laferla, F.M.; et al. Congo red and thioflavin-T analogs detect A β oligomers. *J. Neurochem.* **2008**, *104*, 457–468. [[CrossRef](#)] [[PubMed](#)]
55. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **2012**, *9*, 671–675. [[CrossRef](#)] [[PubMed](#)]

Sample Availability: Samples of the compounds SLF and SLF^{dm} are available from the authors.



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).